All In Biotech

Drug Trial Radar · NCT07287397

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Phase 1/2 Investigation of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (Pioneer-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Oct 15, 2027

Study completion Oct 15, 2027

Sponsor

Lead sponsor
Vector Y TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). Two escalating dose (low dose and high dose) cohorts are planned. The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant. The screening period may last up to 5 weeks to complete screening procedures.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • VTx-002Genetic

    An investigational gene therapy targeting a specific protein.

  • Preventative (Prophylactic) Medication - Corticosteroids: MethylprednisoloneDrug

    To reduce the risk of reactions caused by the study treatment, steroid medicines will be given in advance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
  2. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
  3. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
  4. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: over 5 years
  5. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
  6. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Over 5 years
  7. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: At month 6 and month 12

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • St Joseph's Hospital and medical Center - Barrow Neurological Institute

    Phoenix, Arizona · Not yet recruiting

  • University of California San Diego Medical Center

    San Diego, California · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • The Eleanor & Lou Gehrig ALS Center

    New York, New York · Not yet recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • UMC Utrecht

    Utrecht, Netherlands · Recruiting

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.